Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
Carver
Brett S
BS
Department of Surgery, Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary / Q000601:surgery*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery*; D009392:Nephrectomy / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases